

EXPRESS MAIL CERTIFICATE



Date _____ Label No. _____
I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 by "Express Mail Post Office to Addressee" service.

Name (Print)

Signature

Customer No.: 07278

Docket No.: 03818/100L651-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mladen MERCEP, et al.

Serial No.: 10/615,010

Confirmation No.: TBA

Art Unit: TBA

Filed: July 7, 2003

Examiner: TBA

For: **NOVEL NONSTEROIDAL ANTI-INFLAMMATORY SUBSTANCES,
COMPOSITIONS AND METHODS FOR THEIR USE**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of form PTO/SB/08 (Substitute for Form PTO-1449) and copies of the documents listed thereon.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached form PTO/SB/08) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing form PTO/SB/08 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been

fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

This submission is filed before a first action on the merits has been mailed.


The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

It is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge Deposit Account No. 04-0100 for any deficiency.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: February 2, 2004


Nicholas J. Sisti, Ph.D.
Registration No. 54,453
Agent for Applicant(s)

DARBY & DARBY
Post Office Box 5257
New York, NY 10150-5257
(212) 527-7700



PTO/SB/08a/b (06-03)

Approved for use through 07/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/615,010
				Filing Date	July 7, 2003
				First Named Inventor	Mladen MERCEP
				Art Unit	TBA
				Examiner Name	TBA
Sheet	1	of	3	Attorney Docket Number	03818/100L651-US1


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	4,474,768	10/02/1984	Bright	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	2.	EP 0984019	03/08/2000	Pfizer Products Inc.		
	3.	WO 98/56801	12/17/1998	Pfizer Products Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	4.	Gladue R. P. et al., "In Vitro and In Vivo Uptake of Azithromycin (CP-62,993) by Phagocytic Cells: Possible Mechanism of Delivery and Release at Sites of Infection," <i>Antimicrob. Agents and Chemother.</i> , 33, 1989, 277-282		
	5.	Olsen K. M. et al., "Intrapulmonary Pharmacokinetics of Zithromycin in Healthy Volunteers Given Five Oral Doses," <i>Antimicrob. Agents and Chemother.</i> , 40, 1996, 2582-2585		
	6.	Mikasa, K. et al., "The anti-inflammatory effect of erythromycin in zymosan-induced peritonitis of mice," <i>J. Antimicrob. Chemother.</i> , 30, 1992, 339-348		
	7.	"Discussion, Genomic organization of axolotl 1g genes," <i>J. Immunol.</i> , 159, 1997, 3395-4005		
	8.	Takizawa, H. et al., "Erythromycin Modulates IL-8 Expression in Normal and Inflamed Human Bronchial Epithelial Cells," <i>Am. J. Respir. Crit. Care Med.</i> , 156, 1997, 266-271		
	9.	Labro, M.T., "Anti-inflammatory activity of macrolides: a new therapeutic potential?" <i>J. Antimicrob. Chemother.</i> 41, 1998, 37-46		
	10.	Denis A. et al., "Synthesis and Antibacterial Activity of HMR 36K47, A New Ketolide Highly Potent Against Erythromycin-Resistant and Susceptible Pathogens," <i>Bioorg. & Med. Chem. Lett.</i> 9, 1999, 3075-3080		
	11.	Agouridas C. et al., "Synthesis and Antibacterial Activity of Ketolides (6-O-Methyl-3-oxoerythromycin Derivatives): A New Class of Antibacterials Highly Potent against Macrolide-Resistant and -Susceptible Respiratory Pathogens," <i>J. Med. Chem.</i> , 41, 1998, 4080-4100		
	12.	Sun, Or Y. et al. <i>J. Med. Chem.</i> 2000, 43, 1045-1049		
	13.	Denis A. et al., "Synthesis of 6-O-Methyl-Azithromycin and Its Ketolide Analogue via Beckmann Rearrangement of 9(E)-6-O-Methyl-Erythromycin Oxime," <i>Bioorg. & Med. Chem.</i>		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (06-03)

Approved for use through 07/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/615,010
				Filing Date	July 7, 2003
				First Named Inventor	Mladen MERCEP
				Art Unit	TBA
				Examiner Name	TBA
Sheet	2	of	3	Attorney Docket Number	03818/100L651-US1

	<i>Lett.</i> , 8, 1998, 2427-2432	
14.	Lartey et al., "Synthesis of 4"-Deoxy Motilides: Identification of a Potent and Orally Active Prokinetic Drug Candidate, <i>J. Med. Chem.</i> , 38, 1998, 1793-1798	
15.	Kirst, H.A. et al., "34. Metabolism of macrolides," Bryskier, A. J. et al., Ed. <i>Macrolides, Chemistry, Pharmacology and Clinical Use</i> ; Bryskier, Arnette Blackwell: Paris, 1993; pp 485-491	
16.	Ma, Z. et al., "Discovery and Development of Ketolides as a New Generation of Macrolide Antimicrobial Agents," <i>Current Medicinal Chemistry - Anti-Infective Agents</i> , 1, 2002, 15-34	
17.	Pascual A. et al., "Uptake and intracellular activity of ketolide HMR 3647 in human phagocytic and non-phagocytic cells," <i>Clin. Microbiol. Infect.</i> , 7, 2001, 65-69	
18.	Hand, W. L. et al., "Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes," <i>Int. J. Antimicrob. Agents</i> , 18, 2001, 419-425	
19.	Amsden, G. W., "Advanced-generation macrolides: tissue-directed antibiotics," <i>Int. J. Antimicrob. Agents</i> , 18, 2001, 11-15	
20.	Johnson, J. D. et al., "Antibiotic uptake by alveolar macrophages," <i>J. Lab. Clin. Med.</i> , 95, 1980, 429-439	
21.	Wildfeuer, A. et al., "Uptake of Azithromycin by Various Cells and Its Intracellular Activity under In Vivo Conditions," <i>Antimicrob. Agents Chemother.</i> , 40, 1996, 75-79	
22.	Scoreaux, B. et al., "Intracellular Accumulation, Subcellular Distribution, and Efflux of Tilmicosin in Chicken Phagocytes," <i>Poult. Sci.</i> , 77, 1998, 1510-1521	
23.	Mtairag, E. M. et al., "Investigation of dirithromycin and erythromycylamine uptake by human neutrophils <i>in vitro</i> ," <i>J. Antimicrob. Chemother.</i> 33, 1994, 523-536	
24.	Anderson R. et al., "An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent," <i>J. Antimicrob. Chemother.</i> , 22, 1988, 923-933	
25.	Tasaka, Y. et al., "Rokitamycin Uptake by Alveolar Macrophages," <i>Jpn. J. Antibiot.</i> 41, 1988, 836-840	
26.	Harf, R. et al., "Spiramycin uptake by alveolar macrophages," <i>J. Antimicrob. Chemother.</i> , 22, 1988, 135-140	
27.	Suzuki, T. et al., "General and facile method for determination of configuration of steroid-17-yl-methyl glycolates at C-20 based on kinetic examination," <i>Chem. Soc., Perkin Trans. 1</i> , 1998, 3831-3836	
28.	McLean, H.M. et al., "Novel Fluorinated Antiinflammatory Steroid with Reduced Side Effects: Methyl 9 α -Fluoroprednisolone-16-carboxylate," <i>J. Pharm. Sci.</i> 1994, 83, 476-480	
29.	Little, R.J. et al., "Soft Drugs Based on Hydrocortisone: The Inactive Metabolite Approach and Its Application to Steroidal Antiinflammatory Agents," <i>Pharm. Res.</i> , 16, 1999, 961-967	
30.	Kertesz, D.J. et al., "Thiol Esters from Steroid 17 β -Carboxylic Acids: Carboxylate Activation and Internal Participation by 17 α -Acylates," <i>J. Org. Chem.</i> , 51, 1986, 2315-2328	
31.	Phillipps, G. et al., "Synthesis and Structure - Activity Relationships in a Series of Antiinflammatory Corticosteroid Analogues, Halomethyl Androstane-17 β -carbothioates and 17 β -carboselenoates," <i>J. Med. Chem.</i> 37, 1994, 3717-3729	
32.	Bright, G.M. et al., "Synthesis, In Vitro and In Vivo Activity of Novel 9-Deoxo-9a-AZA-9a-Homoerythromycin A Derivatives; A new Class of Macrolide Antibiotics, the Azalides" <i>J. Antibiot.</i> , 41, 1998, 1029-1047	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (06-03)

Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/615,010
				Filing Date	July 7, 2003
				First Named Inventor	Mladen MERCEP
				Art Unit	TBA
				Examiner Name	TBA
Sheet	3	of	3	Attorney Docket Number	03818/100L651-US1

33.	Costa, A.M. et al., "Hybrids of macrolides and nucleobases or nucleosides," <i>Tetrahedron Letters</i> , 41, 2000, 3371-3375	
34.	Luong et al., "Treatment options for Rheumatoid Arthritis: Celecoxib, Leflunomide, Etanercept, and Infliximab," <i>Ann. Pharmacother.</i> 34, 2000, 743-760	
35.	Taketo, M.M., "Cyclooxygenase 2 Inhibitors in Tumorigenesis (Part II)," <i>J. Natl. Cancer Inst.</i> 90, 1998, 1609-1620	
36.	Fournier, J., "COX-2 and Colon Cancer: Potential Targets for Chemoprevention," <i>J. Cell Biochem. Suppl.</i> 34, 2000, 97-102	
37.	Carswell, E.A., et al., "An endotoxin-induced serum factor that causes necrosis of tumors," <i>Proc. Natl. Acad. Sci. USA</i> 72, 1975, 3666-3670	
38.	Elliot, M., et al., "Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis," <i>Lancet</i> 344, 1994, 1105-1110	
39.	Mori, L., et al., "Attenuation of Collagen-Induced Arthritis in 55-kDa TNF Receptor Type 1 (TNFR1)-IgG1-Treated and TNFR1-Deficient Mice," <i>J. Immunol.</i> 157, 1996, 3178-3182	
40.	Pfeffer, K., et al., "Mice Deficient for the 55 kd Tumor Necrosis Factor Receptor Are Resistant to Endotoxic Shock, yet Succumb to L. monocytogenes Infection," <i>Cell</i> 73, 1993, 457-467	
41.	Georgopoulos, J., "Transmembrane TNF Is Sufficient To Induce Localized Tissue Toxicity and Chronic Inflammatory Arthritis in Transgenic Mice," <i>Inflamm.</i> 46, 1996, 86-97	
42.	Keffer, J., et al., "Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis," <i>EMBO J.</i> 10, 1991, 4025-4031	
43.	Van Assche, et al., "Anti-TNF agents in Crohn's disease," <i>Exp. Opin. Invest. Drugs</i> 9, 2000, 103-111	
44.	Romo, D., et al., "Total Synthesis and Immunosuppressive Activity of (-)-Pateamine A and Related Compounds: Implementation of a β -Lactam-Based Macrocyclization," <i>J. Am. Chem. Soc.</i> 120, 1998, 12237-12254	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

W:\03818\100L651-US1\00116797.DOC

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/92 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Application No. (if known): 10/615,010

Attorney Docket No.: 03818/100L651-US1


Express Mail Certificate Under 37 CFR §1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Airbill No. _____ in an envelope addressed to:


2994069622-US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on February 2, 2004
Date



Signature



Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Information Disclosure Statement (2 pp)

PTO/SB/08 Information Disclosure Statement by Applicant (3 pp)
& 44 References

PTO/SB/92 Express Mail Certificate Under 37 CFR §1.10 (1 p)